SCHEMBL411333

SCHEMBL411333

O=C(O)c1cc(-c2cc(F)cc(F)c2)ccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 10/20 0.65
MCL1 Q07820 6/20 0.65
DHFR P00374 2/20 0.65
HNF4A P41235 1/20 0.65
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
KDM4E B2RXH2 1/20 0.61
MEN1 O00255 1/20 0.61
USP2 O75604 1/20 0.61
ALDH1A1 P00352 1/20 0.61
LMNA P02545 1/20 0.61
TTR P02766 1/20 0.61
ALB P02768 1/20 0.61
HMGB1 P09429 1/20 0.61
HPGD P15428 1/20 0.61
CXCL12 P48061 1/20 0.61
KMT2A Q03164 1/20 0.61
HIF1A Q16665 1/20 0.61
SLC22A6 Q4U2R8 1/20 0.61
HSD17B10 Q99714 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330405 0.87 ACMSD (0.72) ACMSDMCL1DHFRHNF4ACA1
SCHEMBL2771723 0.86 ACMSD (0.83) ACMSDMCL1DHFRHNF4ACA1
SCHEMBL29904854 0.86 ACMSD (0.83) ACMSDMCL1DHFRHNF4ACA1
SCHEMBL3685447 0.86 ACMSD (0.72) ACMSDMCL1DHFRHNF4ACA1
SCHEMBL3695268 0.85 ACMSD (0.70) ACMSDMCL1DHFRHNF4ACA1
SCHEMBL3690106 0.85 ACMSD (0.70) ACMSDMCL1DHFRHNF4ACA1
SCHEMBL22206257 0.84 ACMSD (0.80) ACMSDMCL1DHFRHNF4ACA1
SCHEMBL18224311 0.84 ACMSD (0.88) ACMSDMCL1DHFRHNF4ACA1
SCHEMBL29374831 0.84 ACMSD (0.88) ACMSDMCL1DHFRHNF4ACA1
Methane SCHEMBL28165586 0.84 ACMSD (0.80) ACMSDMCL1DHFRHNF4ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325651-B1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INST (US) 2014-10-08 EP disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-20120309835-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES REVISION THERAPEUTICS, INC. (US) 2012-12-06 US disclosed
US-20120288568-A1 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION REVISION THERAPEUTICS, INC. (US) 2012-11-15 US disclosed
US-20120202885-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES REVISION THERAPEUTICS, INC. (US) 2012-08-09 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
US-20070015827-A1 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation SYTERA, INC. (US) 2007-01-18 US disclosed
WO-2007008821-A2 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION SIRION THERAPEUTICS, INC. (US) 2007-01-18 WO disclosed
US-20060135460-A1 Methods, assays and compositions for treating retinol-related diseases SYTERA, INC. (US) 2006-06-22 US disclosed
WO-2006063128-A2 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS, INC. (US) 2006-06-15 WO disclosed
US-20060057644-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INSTITUTE, THE 2006-03-16 US disclosed
EP-1587821-A2 COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING The Scripps Research Institute (US) 2005-10-26 EP disclosed
US-20040152140-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding THE SCRIPPS RESEARCH INSTITUTE 2004-08-05 US disclosed
WO-2004056315-A2 COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING THE SCRIPPS RESEARCH INSTITUTE (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120288568-A1 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION RBP1, RBP4, ALDH1A2 ACMSD 3843/4885MCL1 4775/4885DHFR 626/4885
US-20070078186-A1 Methods for treating transthyretin amyloid diseases TTR, TTPA, PRNP ACMSD 4308/4885MCL1 3903/4885DHFR 331/4885
US-20120309835-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES RBP1, RBP4, TTR ACMSD 4734/4885MCL1 3642/4885DHFR 287/4885
US-20060135460-A1 Methods, assays and compositions for treating retinol-related diseases RBP1, RBP4, TTR ACMSD 4734/4885MCL1 3642/4885DHFR 287/4885
US-20070015827-A1 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation RBP1, RBP4, ALDH1A2 ACMSD 3843/4885MCL1 4775/4885DHFR 626/4885
US-20120202885-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES RBP1, RBP4, TTR ACMSD 4734/4885MCL1 3642/4885DHFR 287/4885
US-20060057644-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding TTR, TTPA, PRNP ACMSD 4088/4885MCL1 2691/4885DHFR 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.